Search Results

The REAADS IgM anti-B2GPI Test Kit is an in vitro diagnostic assay for the detection and semi-quantitation of IgM anti-B2GPI antibodies in human serum as an aid for assessing the risk of thrombosis in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (antiphospholipid syndrome).

The REAADS IgM anti-B2GPI Test Kit is an enzyme-linked immunosorbent assay (ELISA), utilizing the 96-microwell plate format, similar to the predicate device. Diluted serum samples, calibrator sera, and controls are incubated in microwells coated with purified human Beta-2 Glycoprotein I. Incubation allows the anti-B2GPI antibodies present in the samples to react with the immobilized antigen. After the removal of unbound serum proteins by washing, antibodies specific for human IgM, labeled with horseradish peroxidase (HRP), are added forming complexes with the B2GPI bound antibodies. Following another washing step, the bound enzyme-antibody conjugate is assayed by the addition of a single solution containing tetramethlybenzidine (TMB) and hydrogen peroxide (H2O.) as the chromogenic substrate. The intensity of the color generated is proportional to the serum concentration of anti-B2GPI antibodies. Ontical density is read spectrophotometrically at 450nm. The total incubation time (at room temperature) of the assay is 40 minutes. The assay makes use of a single point calibrator to measure the amount of IgM anti-B2GPI antibodies in patient samples.

Here's a breakdown of the acceptance criteria and study information for the REAADS IgM anti-B2GPI Test Kit, based on the provided text:

Acceptance Criteria and Device Performance

Study Information

2. Sample size used for the test set and the data provenance:

• The text describes "In-house studies" and "clinical studies performed."
• It mentions "unselected SLE patients" but does not specify the exact sample size for these studies.
• The data provenance is not explicitly stated (e.g., country of origin), but it refers to "in-house studies" implying data generated by the manufacturer (Corgenix, Inc., USA). The studies are retrospective as they involve existing patient samples.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• This information is not provided in the document. The ground truth likely refers to the clinical diagnosis of SLE and/or thrombosis risk, but how this was established for the specific samples used in the study is not described.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

• This information is not provided in the document.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• No, an MRMC comparative effectiveness study involving human readers and AI assistance was not done. This device is an in vitro diagnostic (IVD) test kit, not an AI-powered image analysis or diagnostic tool that would involve human readers interpreting AI output. The comparison is between two ELISA test kits.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

• Yes, the performance reported (specificity, sensitivity, correlation) is a standalone performance of the REAADS IgM anti-B2GPI Test Kit itself. As an IVD kit, its measurement output is directly used for diagnostic aid, without a human-in-the-loop component in its direct operation.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

• The ground truth is implied to be clinical diagnosis of systemic lupus erythematosus (SLE) and potentially "risk of thrombosis," as well as the presence of IgM anti-B2GPI antibodies. The studies compare the new device's results to the predicate device and correlate with clinical conditions (SLE).

8. The sample size for the training set:

• The document does not mention a training set in the context of machine learning or AI. This is a traditional diagnostic assay, not an AI/ML product. The "in-house studies" and "clinical studies" likely refer to validation/test sets for the final device.

9. How the ground truth for the training set was established:

• As there's no mention of a "training set" for an AI/ML model, this question is not applicable to the provided document.

Ask a specific question about this device